Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Zedeman, allowing Jichuan to exclusively commercialize Zedeman's product, Zeli Me Benweimode Cream, in mainland China for a total payment of up to 190 million yuan (including tax) [1] Group 1 - Jichuan Pharmaceutical's subsidiary, Jichuan Pharmaceutical Group Co., Ltd., will be responsible for the commercialization of Zedeman's product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The total payment for the agreement, including upfront and milestone payments, will not exceed 190 million yuan [1] - This transaction is expected to enhance the product line of Jichuan Pharmaceutical, contributing to the sustainable development of the company's business and aligning with its strategic goals [1]

Core Insights - Cloudtop New Horizon (HKEX 1952.HK) has signed two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd., which will enhance operational efficiency and commercial capabilities in the cardiovascular disease sector [1][3] Group 1: Strategic Agreements - The commercial service agreement allows Cloudtop New Horizon to leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] - The licensing agreement grants Cloudtop New Horizon exclusive rights for the clinical development, registration, and commercialization of Lerodalcibep in Greater China, enriching its late-stage pipeline [1] Group 2: Financial Terms - Under the licensing agreement, Cloudtop New Horizon will make an initial payment of approximately 205 million yuan, with potential milestone payments not exceeding 212 million yuan for development and regulatory milestones, and up to 1.977 billion yuan for sales milestones, along with potential royalties based on net sales [1] Group 3: Product Overview - Lerodalcibep, developed by LIB Therapeutics, is a third-generation PCSK9 inhibitor designed to lower LDL-C levels in patients with high cholesterol, including heterozygous familial hypercholesterolemia [2] - The product is designed for convenient monthly subcutaneous injection and has shown significant efficacy in clinical trials, with applications submitted to the FDA and EMA, and a BLA submission expected in mid-2026 in Greater China [2] Group 4: Industry Implications - This collaboration is seen as a critical step in strengthening Cloudtop New Horizon's full industry chain layout, aligning with its long-term development strategy and enhancing its core competitiveness [3]